The Cooper Companies, Inc.

coopercos.com

What Do They Do?

Sells contact lenses through eye-care providers and retailers, and fertility and women’s-health products and services to medical offices, hospitals, surgery centers and fertility clinics.

How Do They Make Money?

Most money comes from contact lenses, with product sales counted when shipped or delivered. Other product sales are counted at shipment or delivery; services are counted when provided or over the service period, including cord storage over contract terms.

revenue

Segment	Share	Revenue	How money arrives
CooperVision Sold outright	67% FY2022: 68%		Sold outright
CooperSurgical	33% FY2022: 32%

Who Are Their Customers?

CooperVision sells through its own field representatives and distributors to eye-care practitioners, optical chains and mass merchandisers. CooperSurgical uses field sales, inside sales and distributors, and also reaches consumers directly.

Do Revenues Turn Into Profits?

Yes. It kept 9 cents of every revenue dollar as net income in FY2025 and turned 11 cents into free cash flow.

Operating income, FY2025

17% of revenue

▼ −3% vs FY2024 ($705.7M, 18%)

Net income, FY2025

9% of revenue

▼ −4% vs FY2024 ($392.3M, 10%)

Free cash flow, FY2025

11% of revenue

▲ +51% vs FY2024 ($288.1M, 7%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q3 FY2026, the three months to Jul 31, 2026

Revenue: ▲ +1%; vs $1.1B in Q3 FY2025
Net income: ▲ +340%; vs $98.3M in Q3 FY2025

CooperVision share of revenue vs 67.8% in Q3 FY2025

Sep 9, 2026 Company updated fiscal 2026 revenue and earnings guidance Fiscal 2026 total revenue guidance is $4.229 - $4.252 billion, and non-GAAP diluted EPS guidance is $4.51 - $4.55.
Jun 4, 2026 Company reached settlements covering over 95% of fertility media recall claimants The company accrued $324.1 million in litigation liabilities, offset by $52.5 million of expected insurance recoveries.

Growing. Revenue grew 40% in 4 years, from $2.9B in FY2021 to $4.1B in FY2025, about 9% a year.

Revenue over time

CooperVision CooperSurgical

$5B$2.5B$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Johnson & Johnson, Alcon, Bausch + Lomb, Vitrolife Group, Nexpring, Fairfax Cryobank, Fairfax EggBank, Baxter International, Medtronic, Hologic, Revvity, Bayer, AbbVie, and Organon

Comments